Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rimonabant for treatment of nonalcoholic steatohepatitis in patients with type 2 diabetes mellitus
2007-003013-14Phase 3Completed
- Sponsor
- Sanofi
- Start
- Aug 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in metabolic dysfunction-associated steatohepatitis (MASH) and type 2 diabetes mellitus (T2DM) comparing Rimonabant 20 mg once daily with Placebo once daily (2 arms). Primary endpoint: Change in NAFLD Activity Score (NAS). Started Aug 2007; status: completed.
02
Drugs
rimonabant
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-003013-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-003013-14.